Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005258 | 1.00 | BUB1 (0.33) | BUB1USP2SMN1; SMN2ALDH1A1NR1H2 | |
| SCHEMBL31751833 | 0.90 | USP2 (0.34) | BUB1USP2SMN1; SMN2NR1H2EPHX2 | |
| SCHEMBL15106078 | 0.85 | GRIN2B (0.32) | USP2SMN1; SMN2NR1H2EPHX2GRIN2B | |
| SCHEMBL10174274 | 0.84 | USP2 (0.34) | BUB1USP2SMN1; SMN2NR1H2EPHX2 | |
| SCHEMBL28371753 | 0.84 | USP2 (0.34) | BUB1USP2SMN1; SMN2NR1H2EPHX2 | |
| SCHEMBL1268754 | 0.84 | POLB (0.31) | BUB1USP2SMN1; SMN2NR1H2 | |
| SCHEMBL14486969 | 0.79 | GPR119 (0.36) | USP2SMN1; SMN2NR1H2EPHX2GRIN2B | |
| SCHEMBL18639721 | 0.78 | USP2 (0.37) | BUB1USP2SMN1; SMN2ALDH1A1NR1H2 | |
| SCHEMBL11954515 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2ALDH1A1NR1H2EPHX2 | |
| SCHEMBL11954522 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2ALDH1A1NR1H2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2175933-B1 | TRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| EP-2175933-A1 | TRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009015254-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | ABL1, STK25, FLT3 | BUB1 209/4885USP2 1922/4885SMN1; SMN2 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.